KDA Group Inc. (TSXV:KDA) acquired Covapharm Inc for CAD 0.38 million on December 16, 2022. consideration of CAD 200,000.00 payable in monthly instalments of CAD10,000.00 over a period of twenty months from the closing date and a maximum of 1,825,000 Class A shares in the capital stock of the Corporation. Stéphane Côté will become a consultant to KDA. The issuance of the KDA Shares is subject to the approval of the TSX Venture Exchange.

KDA Group Inc. (TSXV:KDA) completed the acquisition of Covapharm Inc on December 16, 2022. As of January 13, 2022, the TSX Venture Exchange has accepted for filing documentation of the share purchase agreement.